Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:17:25.432Z.
Calculation as of: 2026-10-06T15:17:25.432Z.
Quote observation: 2026-10-06T15:15:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7de7752a9f7c92cf302168b3adc2b8952dbd3ee015c15fa7e623ade4200d4f53
PE RATIO
N/A
Market Cap
$838.66M
PE Ratio
N/A
TTM Avg
351.06
3Y Avg
351.06
5Y Avg
351.06
Market Cap
$860.85M
PE Ratio
N/A
TTM Avg
76.88
3Y Avg
76.88
5Y Avg
76.88
Market Cap
$797.15M
PE Ratio
N/A
TTM Avg
694.69
3Y Avg
438.87
5Y Avg
438.87
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Jade Biosciences, Inc. (JBIO) | $833.81M | N/A | N/A | N/A | N/A |
| Beta Bionics, Inc. (BBNX)vs › | $837.47M | N/A | N/A | N/A | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.66M | N/A | 351.06 | 351.06 | 351.06 |
| Alumis Inc. (ALMS)vs › | $837.49M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $818.90M | N/A | 197.34 | 197.34 | 197.34 |
| InMode Ltd. (INMD)vs › | $804.44M | 11.38 | 9.51 | 9.54 | 15.29 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $860.85M | N/A | 76.88 | 76.88 | 76.88 |
| Apnimed, Inc. (APMD)vs › | $803.78M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $797.15M | N/A | 694.69 | 438.87 | 438.87 |
| Geron Corporation (GERN)vs › | $785.86M | N/A | 973.22 | 973.22 | 973.22 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$13.70
Forward EPS (Est.)
$-2.95
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
